The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Hosted on MSN18h
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Decision day for federal workers
MATERNAL DEATH RATES FALL — Fewer women died during pregnancy, childbirth and the postpartum period in 2023, but disparities in death rates between white women and women of color widened, POLITICO’s ...
Hosted on MSN20h
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...